Table 1.
PD-1/PD-L1 Antibodies in Clinical Development
| Target | Agent Name | Class | Phase | Company | Companion PD-L1 Detection Antibody |
|---|---|---|---|---|---|
| PD-1 | Nivolumab (BMS-936558, MDX1106) | Human IgG4 | Approved by FDA, EMA, Japan | BMS, Ono pharmaceutical | 28–8, Epitomics/Dako |
| Pembrolizumab (MK-3475, lambrolizumab) | Humanized IgG4k | Approved by FDA | Merck & Co | 22C3, Dako/Merck | |
| Pidilizumab (CT-011) | Humanized IgG1k | 2 (DLBCL) | Cure Tech | ||
| AMP-224 | Fusion protein of PD-L2 and Fc domain of human IgG | 1 | Amplimmune/GSK | ||
| AMP-514 (MEDI0680) | Humanized IgG4k | 1 | Amplimmune/GSK | ||
| PDR001 | Humanized IgG4 | 1 | Novartis | ||
| REGN2810 | Human monoclonal antibody | 1 | Regeneron | ||
| BGB A317 | Humanized monoclonal antibody | 1 | BeiGene | ||
| SHR-1210 | Monoclonal antibody | 1 | Atridia | ||
| PD-L1 | Atezolizumab (MPDL3280A) | Fully humanized IgG1 | 3 | Roche | SP142, Spring Bioscience/ Ventana/ Roche |
| Durvalumab (MEDI4736) | Human IgG1k | 3 | MedImmune/ AZ | SP263, Spring Bioscience/ Ventana/ Roche | |
| Avelumab (MSB0010718C) | Human IgG1 | 3 | Merck KGaA | Dako | |
| BMS-936559 (MDX1105) | Human IgG4 | 1 | BMS | 28–8, Epitomics/Dako |
PD-1, programmed death protein 1; PD-L1, programmed death ligand 1; IgG, immunoglobulin G; FDA, U.S. Food and Drug Administration; EMA, European Medicines Agency; DLBCL, diffuse large B-cell lymphoma; BMS, Bristol-Myers Squibb; GSK, GlaxoSmithKline; AZ, AstraZeneca.